Avita Medical to be eligible for NTAP reimbursement from CMS for RECELL

AVITA Medical (RCEL) announced that beginning October 1, 2025, hospitals across the U.S. will be eligible for New Technology Add-on Payment, NTAP, reimbursement from the Centers for Medicare & Medicaid Services, CMS, when RECELL is used to treat acute, non-burn trauma and surgical full-thickness wounds. This designation will remain in effect through September 30, 2026, providing hospitals with supplemental reimbursement of up to $4,875 per case in addition to the standard CMS payment. The NTAP was granted under CMS’ alternative NTAP pathway, which recognizes the transformative nature of products that have received Breakthrough Device designation from the U.S. Food and Drug Administration.